TP53 and acute myeloid leukemia: There are authors who have demonstrated that APR- 246 was well tolerated with a clinical response and remissions because it was capable of restoring wild-type p53 function in malignant cells administered in combination with azacytidine in patients with TP53-mutant myeloproliferative neoplasms, such as acute myeloid leukaemia (ClinicalTrials.gov identifier: NCT03072043) [110].